Сравнение in vitro конъюгатов аффибоди для HER-2 терапии, содержащих альбумин-связывающий домен и полипептид PAS
| Parent link: | Курзина, И. А. (химик ; 1972-). Перспективы развития фундаментальных наук=Prospects of Fundamental Sciences Development: сборник научных трудов XX Международной конференции студентов, аспирантов и молодых ученых, г. Томск, 25-28 апреля 2023 г..— .— Томск: Изд-во ТПУ Т. 4 : Биология и фундаментальная медицина.— 2023.— С. 21-23 |
|---|---|
| Автор: | |
| Співавтор: | |
| Інші автори: | |
| Резюме: | Заглавие с экрана In this study, we conducted an in vitro study comparing the potential of targeted therapeutic drugs containing a cytotoxic agent mc-DM1. The therapeutic potential of using an HER2-targeting Affibody molecule fused to an albumin-binding domain (ABD) to increase half-life and conjugated to the cytotoxic maytansine derivative, MC-DM1, has previously been confirmed. In this study, we also investigated the potential of a targeted therapeutic conjugate that includes an Affibody molecule targeting HER2 and the cytotoxic agent MC-DM1, and the PAS600 polypeptide was the hallmark of the drug design. PAS polypeptides represent a novel class of biosynthetic polymers comprising repetitive sequences of the small proteinogenic amino acids L-proline, L-alanine and/or L-serine. In this study, PAS600 used to increase the half-life of the drug. We conducted in vitro studies comparing the potential of the new (HE)3-ZHER2-Cys/DM1-PAS600 variant molecule with the previously studied (HE)3-ZHER2-ABD-Cys/DM1 molecule Текстовый файл |
| Мова: | Російська |
| Опубліковано: |
2023
|
| Предмети: | |
| Онлайн доступ: | http://earchive.tpu.ru/handle/11683/80620 |
| Формат: | Електронний ресурс Частина з книги |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=675063 |
| Резюме: | Заглавие с экрана In this study, we conducted an in vitro study comparing the potential of targeted therapeutic drugs containing a cytotoxic agent mc-DM1. The therapeutic potential of using an HER2-targeting Affibody molecule fused to an albumin-binding domain (ABD) to increase half-life and conjugated to the cytotoxic maytansine derivative, MC-DM1, has previously been confirmed. In this study, we also investigated the potential of a targeted therapeutic conjugate that includes an Affibody molecule targeting HER2 and the cytotoxic agent MC-DM1, and the PAS600 polypeptide was the hallmark of the drug design. PAS polypeptides represent a novel class of biosynthetic polymers comprising repetitive sequences of the small proteinogenic amino acids L-proline, L-alanine and/or L-serine. In this study, PAS600 used to increase the half-life of the drug. We conducted in vitro studies comparing the potential of the new (HE)3-ZHER2-Cys/DM1-PAS600 variant molecule with the previously studied (HE)3-ZHER2-ABD-Cys/DM1 molecule Текстовый файл |
|---|